CNR Institutional Research Information System

PIZZINI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.846
NA - Nord America 1.328
EU - Europa 551
SA - Sud America 439
Continente sconosciuto - Info sul continente non disponibili 103
AF - Africa 46
OC - Oceania 6
Totale 4.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.221
SG - Singapore 833
CN - Cina 366
BR - Brasile 337
IT - Italia 218
HK - Hong Kong 195
VN - Vietnam 190
FR - Francia 128
BD - Bangladesh 64
CA - Canada 53
KR - Corea 47
GB - Regno Unito 36
IN - India 36
DE - Germania 30
NL - Olanda 29
AR - Argentina 24
FI - Finlandia 23
CO - Colombia 19
JP - Giappone 18
EC - Ecuador 17
ID - Indonesia 16
VE - Venezuela 13
RU - Federazione Russa 12
JM - Giamaica 11
PE - Perù 11
IE - Irlanda 10
PL - Polonia 10
TR - Turchia 10
MX - Messico 9
ZA - Sudafrica 9
ES - Italia 8
PH - Filippine 8
CR - Costa Rica 7
IQ - Iraq 7
MA - Marocco 7
SA - Arabia Saudita 7
UY - Uruguay 7
AT - Austria 6
IL - Israele 6
MY - Malesia 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
HN - Honduras 5
HR - Croazia 5
KE - Kenya 5
PK - Pakistan 5
SE - Svezia 5
UA - Ucraina 5
AU - Australia 4
BO - Bolivia 4
CL - Cile 4
NI - Nicaragua 4
NP - Nepal 4
AL - Albania 3
AO - Angola 3
BB - Barbados 3
BE - Belgio 3
ET - Etiopia 3
GT - Guatemala 3
PY - Paraguay 3
TH - Thailandia 3
TN - Tunisia 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
MT - Malta 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
RO - Romania 2
TW - Taiwan 2
AZ - Azerbaigian 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MR - Mauritania 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
Totale 4.209
Salva come PNG Salva come JPEG
Città #
Singapore 528
Santa Clara 278
Hong Kong 194
San Jose 138
Hefei 105
Ashburn 104
Lauterbourg 104
Ho Chi Minh City 74
Beijing 67
Los Angeles 51
Seoul 47
Hanoi 45
New York 33
Dallas 31
São Paulo 27
Milan 20
Buffalo 16
Frankfurt am Main 14
Rome 12
Toronto 12
Helsinki 10
Rio de Janeiro 10
Tokyo 10
Chicago 9
Curitiba 9
Dublin 9
Brasília 8
Brooklyn 8
Council Bluffs 8
Düsseldorf 8
Miami 8
Montreal 8
Warsaw 8
Amsterdam 7
Biên Hòa 7
Da Nang 7
Lappeenranta 7
Orem 7
The Bronx 7
Atlanta 6
Baghdad 6
Belo Horizonte 6
Dhaka 6
Guayaquil 6
Haiphong 6
Lima 6
Louisville 6
Philadelphia 6
Quito 6
Tampa 6
Turku 6
Washington 6
Austin 5
Bengaluru 5
Bologna 5
Boston 5
Catania 5
Chennai 5
Florence 5
Kingston 5
Las Vegas 5
Minamishinagawa 5
Naples 5
New Orleans 5
Phoenix 5
Salvador 5
San José 5
Zagreb 5
Bari 4
Belém 4
Cleveland 4
Denver 4
Ha Long 4
Houston 4
Hải Dương 4
Jakarta 4
Johannesburg 4
Joinville 4
London 4
McAllen 4
Medellín 4
Mumbai 4
New Delhi 4
Paris 4
Paternò 4
Queens 4
Sheffield 4
Stockholm 4
Vienna 4
Addis Ababa 3
Barquisimeto 3
Bogotá 3
Bridgetown 3
Cairo 3
Cali 3
Cape Town 3
City of London 3
Delhi 3
Formosa 3
Fort Lauderdale 3
Totale 2.330
Salva come PNG Salva come JPEG
Nome #
Role of Gut Microbiota in Overweight Susceptibility in an Adult Population in Italy 132
8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease 130
Osteopontin, death and cardiovascular events in stage G3–4 CKD patients: a joint model analysis 91
Socioeconomic Status and Clinical Outcomes in Chronic Kidney Disease: Bootstrap Validation of a Simple Indicator 88
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients 87
Il peptide natriuretico (BNP) è un biomarcatore della congestione polmonare nei pazienti in dialisi. 77
Osteopontin and Clinical Outcomes in Hemodialysis Patients 77
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass 77
Plasma levels of myeloperoxidase and resistin independently predict mortality in dialysis patients 71
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients 70
Quality of life and kidney function in CKD patients: a longitudinal study 70
Inflammation biomarkers and inflammatory genes expression in metabolically healthy obese patients 68
Reducing salt intake by urine chloride self-measurement in non-compliant patients with chronic kidney disease followed in nephrology clinics: a randomized trial 67
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass 67
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension 66
Perioperative Marinobufagenin (MBG) Measurement May Improve Acute Kidney Injury Risk Assessment in Patients Undergoing Major Cardiac Surgery: A Proof-of-Concept Study 64
CKD-MBD biomarkers and CKD progression: an analysis by the joint model 61
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study 57
Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD 56
Salt intake correlates with night systolic blood pressure in non-dialytic chronic kidney disease 56
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity 55
FGF23 and the PTH response to paricalcitol in chronic kidney disease 55
Intact FGF23 and ?-klotho during acute inflammation/sepsis in CKD patients 52
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 50
Neuropeptide Y and chronic kidney disease progression: a cohort study 50
Procalcitonin and the inflammatory response to salt in essential hypertension: A randomized cross-over clinical trial 47
Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. 47
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients 47
Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients 47
Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial 46
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 45
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients 45
Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial 43
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. 42
Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients 42
L'obesità addominale interagisce con due citochine prodotte dal tessuto adiposo, Leptina ed Adiponectina, per predire il rischio di mortalità totale e cardiovascolare nei pazienti in dialisi. 41
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD) 41
I polimorfismi del gene ENPP1 si associano ad ipertrofia ventricolare sinistra ed alla funzione sistolica nei pazienti in dialisi. 41
Long term predictors of cerebrovascular events in patients with end stage renal disease (ESRD). 40
INDICES OF INSULIN RESISTANCE AND RISK OF TOTAL AND CARDIOVASCULAR MORTALITY IN DIALYSIS PATIENTS 39
Vitamin D and methylarginines in chronic kidney disease (CKD) 39
C-Reactive Protein and Interleukin-6 modify the risk of high levels of Asymmetric Dimethyl-Arginine (ADMA) for death and cardiovascular events in end stage renal diseases patients. 37
Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. 36
Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD). 36
Vitamin D receptor activation by paricalcitol and insulin resistance in CKD 35
Il rischio di progressione delle nefropatie croniche e mortalità: ruolo dell'Asymmetrical Di-Methil-Arginine (ADMA). 34
Leptin and biochemical markers of bone turnover in dialysis patients 33
Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial 33
Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. 33
Association between resistin levels and all-cause and cardiovascular mortality: A new study and a systematic review and meta-analysis 33
Low triiodothyronine and survival in end stage renal disease (ESRD). 33
Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels 33
Urotensin II and cardiomyopathy in end-stage renal disease. 32
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in ckd patients. 32
FGF23 beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease patients. 32
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease 32
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 31
Pattern evolutivo dei biomarcatori di infiammazione e dei fattori di rischio non tradizionali dopo trapianto renale. 30
Low triiodothyronine and survival in end-stage renal disease. 30
Urotensin II is inversely related to markers of endothelial activation and inflammation and is an inverse predictor of incident cardiovascolar events in end stage renal disease (ESRD). 29
Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. 29
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end stage renal disease (ESRD). 29
L'infiammazione amplifica il rischio di mortalità ed eventi cardiovascolari connesso ai livelli circolanti di dimetilarginina asimmetrica (ADMA) nei pazienti in dialisi. 29
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease 28
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 28
Vascular endothelial growth factor (VRGF) is a marker of left ventricular dysfunction and predicts mortality in hemodialysis (HD) patients. 28
Asymmetric Dimethylarginine (ADMA) Enzymatic Machinery and Adipokines Gene Expression in the Adipose Tissue in Stage 3-5 CKD patients. 28
Vitamin D levels and patient outcome in chronic kidney disease. 27
L'iperparatiroidismo e il TNF-a come determinanti dell'incidenza di fratture nei pazienti in dialisi: uno studio di coorte. 27
Vascular Endothelial Growth Factor, rimodellamento ventricolare sinistro e disfunzione sistolica nei pazienti in dialisi 27
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 27
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 27
Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients 27
Waist circumference modifies the relationship of adipose tissue cytochines leptin and adiponectin with all-cause and cardiovascular mortality in end stage renal disease (ESRD). 27
Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcome stage renal disease patients. 26
Low Triiodothyronine and Cardiomyopathy in Patients with End-Stage Renal Disease (ESRD). 26
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 26
Urotensin II partecipates in cardiovascular control in end stage renal disease (ESRD). 25
Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides 25
Beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease (CKD) patients. 25
Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease 24
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. 24
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 24
Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. 24
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 23
Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study 23
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). 23
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in CKD patients. 23
I predittori degli eventi cardiovascolari nei pazienti in dialisi. 23
L'ipotiroidismo subclinico si associa alla micro-infiammazione cronica e predice la mortalità nei pazienti in CAPD. Risultati di uno studio pilota di coorte. 23
Smoking and hyperparathyroidism in patients with end stage renal disease (ESRD). 22
Valore diagnostico per il basso turnover osseo del PTH dosato con metodi RIA di prima e seconda generazione. 22
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. 21
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 21
Vascular endothelial growth factor, left ventricular remodeling and systolic dysfunction in end stage renal disease 21
Low triiodothyronine: a new facet of inflammation in end-stage renal disease. 21
Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections 21
Which is the best inflammation marker? A comparative study based on multivariate modelling of mortality in end stage renal disease (ESRD) patients. 20
BRAIN NATRIURETIC PEPTIDE AS A BIOMARKER OF PULMONARY CONGESTION IN STAGE 5 CKD ON DIALYSIS 20
Thyroid sick syndrome e miocardiopatia nei pazienti con insufficienza renale cronica. 19
Totale 4.093
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.678
article - articoli 10.422
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202439 0 0 0 0 0 0 0 0 32 0 7 0
2024/20251.487 6 12 115 91 307 27 33 103 44 58 376 315
2025/20262.226 96 199 226 313 412 87 346 159 95 138 102 53
2026/2027567 203 110 254 0 0 0 0 0 0 0 0 0
Totale 4.319